Ann Merrifield

Chair of the Board
Nominating and Corporate Governance Committee (Chair)
Audit Committee (Member)

Ms. Merrifield most recently was President and Chief Executive Officer at PathoGenetix, a genomics company that developed and commercialized an automated system for rapid bacterial identification from complex samples.

Before joining PathoGenetix in 2012, Ms. Merrifield spent 18 years at the Genzyme Corporation, serving in a number of leadership roles. In her most recent position, she was selected by the CEO to serve as Senior Vice President, Business Excellence for two years before the Sanofi acquisition. Prior to that, she served as President of Genzyme Biosurgery, where she led a turnaround from an over $75M loss in 2002 to a profit of more than $200M in 2009. She served as President of Genzyme Genetics before her position at Genzyme Biosurgery, where she shaped the company’s genetic diagnostics business through product and service differentiation and strategic acquisitions.

Ms. Merrifield came to Genzyme from Bain and Company, where she was a partner, and Aetna Life & Casualty, where her role was as an investment officer. She earned a Bachelor of Arts in zoology and a Master of Education from the University of Maine, and a Master of Business Administration from the Amos Tuck School of Business at Dartmouth College.

She serves as Trustee and Director on a number of boards, including Flexion Therapeutics, Partners Continuing Care, and the YMCA of Greater Boston.